Octagam Immune Globulin (Human)

LOE Approaching

immune globulin

BLAINTRAVENOUSSOLUTION
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Pharmacologic Class:

Antigen Neutralization

Clinical Trials (5)

NCT06980480Phase 3Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Started Jan 2026
183 enrolled
Multiple MyelomaSecondary Immunodeficiency
NCT06565078N/ARecruiting

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Started Feb 2025
100 enrolled
Primary Immunodeficiency Diseases (PID)
NCT05382650N/ATerminated

Survey of Human Rabies Immune Globulin Safety in Children

Started Feb 2023
NCT04638634Phase 1Terminated

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Started Feb 2021
12 enrolled
Coronavirus Disease 2019 (COVID-19)
NCT04565015Phase 3Active Not Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Started Dec 2020